LATE BREAKING: ANDES TRIAL AT TCT 2025
DOACs Offer Safer Profile but No Added Efficacy in Preventing Device-Related Thrombosis After LAAO
This news is covered by the Medical Dialogues Bureau present at the TCT Conference 2025, being held in San Francisco, USA.
Short-term use of direct oral anticoagulants (DOACs) following left atrial appendage closure (LAAC) did not significantly reduce device-related thrombosis (DRT) compared with dual antiplatelet therapy (DAPT).
However, DOACs were associated with a notably better safety profile, primarily due to reduced bleeding events, based on findings from the ANDES trial presented at TCT 2025, San Francisco and simultaneously published in Circulation.
The ANDES trial, the largest of its kind, was conducted across 13 centers in Canada and Europe between 2018 and 2025.
Josep Rodés-Cabau of Laval University, Quebec, led the study aimed to identify the optimal short-term antithrombotic strategy following LAAC in patients with non-valvular atrial fibrillation (NVAF).
Author summary: DOACs offer safer profile after LAAO.
More News
- Here’s why Utah’s Olympic organizers are in NYC this week
- Two US Navy Aircraft and a Helicopter Crash in South China Sea, All Crew Rescued
- OPPO, Ballet Philippines to promote Filipino Artistry with new partnership
- Angola seeks to purchase Anglo American’s 85% stake in De Beers
- Older Patients and Women Bear the Brunt of CTD-ILD Burden
- The main PlayStation Plus Essential monthly game for November has seemingly been leaked | VGC
- Moody’s maintains BPC rating despite gov't downgrade
- Kymera Therapeutics, Inc.: Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
- The opposite of “turbo cancer”: COVID-19 vaccines sensitize cancer to immunotherapy
- London midday: FTSE nudges up amid trade deal hopes; HSBC falls